{"id":476426,"date":"2020-03-26T13:48:02","date_gmt":"2020-03-26T13:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476426"},"modified":"2020-03-26T13:48:02","modified_gmt":"2020-03-26T13:48:02","slug":"hypereosinophilic-syndrome-market-size-share-trend-epidemiology-market-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypereosinophilic-syndrome-market-size-share-trend-epidemiology-market-forecast-to-2030_476426.html","title":{"rendered":"Hypereosinophilic Syndrome Market Size, Share, Trend, Epidemiology & Market Forecast to 2030"},"content":{"rendered":"
\"Hypereosinophilic<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hypereosinophilic Syndrome, historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

The Hypereosinophilic Syndrome market report covers emerging drugs, current treatment practices, Hypereosinophilic Syndrome market share of the individual therapies, current and forecasted Hypereosinophilic Syndrome Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report also provides detailed current Hypereosinophilic Syndrome treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/span><\/p>\n


<\/span><\/span>Hypereosinophilic Syndrome Market Key Facts<\/strong><\/p>\n

As per the study by Baltazares-Lipp et al.,  the exact epidemiology of HES is not known yet, but it is estimated that 90% of patients are men; the majority of the cases occur between 20–50 years of age, with a peak in the fourth decade of life. HES is a possibly fatal disease, with a survival rate of less than 50% after 10-year follow-up.<\/p>\n

According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Hypereosinophilic Syndrome<\/span><\/p>\n

According to the study “World Health Organization-defined eosinophilic disorders: 2015 <\/span>update on diagnosis, risk stratification, and management” by Gotlib et al. revealed there were 131 incident cases of HS between 2001–2005, the male-to-female ratio was 1.47, and the rates increased with the age of 65–74 years.<\/p>\n

 \"\"<\/p>\n

Visit For Sample Pages: <\/span><\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/hypereosinophilic-syndrome-market<\/a><\/p>\n

 <\/strong><\/p>\n

Key Benefits of Hypereosinophilic Syndrome Market Report<\/span><\/strong><\/p>\n

Hypereosinophilic Syndrome market report provides an in-depth analysis of Hypereosinophilic Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/span><\/p>\n

The Hypereosinophilic Syndrome market report will help in developing business strategies by understanding the Hypereosinophilic Syndrome Market trends & developments, key players and future market competition that will shape and drive the Hypereosinophilic Syndrome market in the upcoming years.<\/span><\/p>\n

The Hypereosinophilic Syndrome market report covers Hypereosinophilic Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.<\/span><\/p>\n

The report provides a detailed assessment of the Hypereosinophilic Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. <\/span><\/p>\n

 <\/p>\n

Hypereosinophilic Syndrome Market<\/a><\/p>\n

The Hypereosinophilic Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hypereosinophilic Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. <\/p>\n

The report gives a thorough detail of Hypereosinophilic Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. <\/p>\n

 <\/p>\n

Hypereosinophilic Syndrome Epidemiology<\/a><\/p>\n

The Hypereosinophilic Syndrome epidemiology section covers insights about historical and current Hypereosinophilic Syndrome patient pool and forecasted trend for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/span><\/p>\n

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/span><\/p>\n

 <\/p>\n

Hypereosinophilic Syndrome Drugs Uptake and Key Market Players<\/a><\/p>\n

Hypereosinophilic Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypereosinophilic Syndrome market or expected to get launched in the market during the study period. The analysis covers Hypereosinophilic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.    <\/span><\/p>\n

Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Benralizumab, Mepolizumab, Knopp Biosciences are some of the emerging therapies in the Hypereosinophilic<\/span> Syndrome market. <\/span>The major key players in the Hypereosinophilic<\/span> Syndrome<\/span> market include AstraZeneca, GlaxoSmithKline, Knopp Biosciences and others. <\/span><\/p>\n

 <\/span><\/span><\/p>\n

Table of Contents<\/span><\/strong><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary <\/span><\/p>\n

3. Hypereosinophilic Syndrome Competitive Intelligence Analysis<\/span><\/p>\n

4. Hypereosinophilic Syndrome Market Overview at a Glance<\/span><\/p>\n

5. Hypereosinophilic Syndrome Disease Background and Overview<\/span><\/p>\n

6. Hypereosinophilic Syndrome Patient Journey<\/span><\/p>\n

7. Hypereosinophilic Syndrome Epidemiology and Patient Population<\/span><\/p>\n

8. Hypereosinophilic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

9. Hypereosinophilic Syndrome Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Hypereosinophilic Syndrome Treatment<\/span><\/p>\n

11. Hypereosinophilic Syndrome Marketed Products<\/span><\/p>\n

12. Hypereosinophilic Syndrome Emerging Therapies<\/span><\/p>\n

13. Hypereosinophilic Syndrome Seven Major Market Analysis<\/span><\/p>\n

14. Attribute Analysis<\/span><\/p>\n

15. Hypereosinophilic Syndrome Market Outlook (7 major markets)<\/span><\/p>\n

16. Hypereosinophilic Syndrome Access and Reimbursement Overview<\/span><\/p>\n

17. KOL Views on the Hypereosinophilic Syndrome Market.<\/span><\/p>\n

18. Hypereosinophilic Syndrome Market Drivers<\/span><\/p>\n

19. Hypereosinophilic Syndrome Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

 <\/span><\/span><\/p>\n

About<\/strong> <\/span>DelveInsight<\/a><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Ankit Nigam
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research DelveInsight’s “Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hypereosinophilic Syndrome, historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market trends in the United States, EU5 (Germany, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-476426","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476426"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}